Keywords: strong, results, b-ms/otsuka, abilify, drug, major, bristol-myers
Strong results for B-MS/Otsuka's Abilify
Article | 20 March 2006
US drug major Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical says that their co-devloped antipsychotic, Abilify (aripiprazole) demonstrated statistically-superior effectiveness to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
